Advances on the understanding of the origins of synaptic pathology in AD

Current Genomics

Volumn 8, Issue 8, 2007, Pages 486-508

  Lacor, Pascale Nathalie ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; MEMBRANE RECEPTOR; NEUROTOXIN; OLIGOMER;

ALZHEIMER DISEASE; COGNITION; CONSENSUS; DENDRITIC SPINE; HUMAN; HYPOTHESIS; IMMUNOTHERAPY; NERVE CELL NECROSIS; NEUROFIBRILLARY TANGLE; NONHUMAN; PATHOGENESIS; PROTEIN CONFORMATION; REVIEW; SYNAPSE; TRANSGENIC MOUSE;

MUS;

EID: 41549115893     PISSN: 13892029     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920207783769530     Document Type: Review

References (358)

1. Hebert, L.E., Scherr, P.A., Bienias, J.L., Bennett, D.A., Evans, D.A. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol. 2003, 60: 1119-1122.
2. Morris, J.C., Cummings, J. Mild cognitive impairment (MCI) represents early-stage Alzheimer's disease. J. Alzheimers Dis. 2005, 7: 235-239.
3. Albert, M.S., Blacker, D. Mild cognitive impairment and dementia. Annu. Rev. Clin. Psychol. 2006, 2: 379-388.
4. Cummings, J.L., Vinters, H.V., Cole, G.M., Khachaturian, Z.S. Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology 1998, 51: S2-17.
5. Selkoe, D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001, 81: 741-766.
6. Ertekin-Taner, N. Genetics of Alzheimer's disease: a centennial review. Neurol. Clin. 2007, 25: 611-67.
7. Corder, E.H., Saunders, A.M., Strittmatter, W.J., Schmechel, D.E., Gaskell, P.C., Small, G.W., Roses, A.D., Haines, J.L., Pericak-Vance, M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261: 921-923.
8. Bertram, L., Tanzi, R.E. The current status of Alzheimer's disease genetics: what do we tell the patients? Pharmacol. Res. 2004, 50: 385-396.
9. Kamboh, M.I. Molecular genetics of late-onset Alzheimer's disease. Annu. Hum. Genet. 2004, 68: 381-404.
10. De la Monte, S.M., Tong, M., Lester-Coll, N., Plater, M.Jr., Wands, J.R. Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. J. Alzheimers Dis. 2006, 10: 89-109.
11. Rogaeva, E., Meng, Y., Lee, J.H., Gu, Y., Kawarai, T., Zou, F., Katayama, T., Baldwin, C.T., Cheng, R., Hasegawa, H., Chen, F., Shibata, N., Lunetta, K.L., Pardossi-Piquard, R., Bohm, C., Wakutani, Y., Cupples, L.A., Cuenco, K.T., Green, R.C., Pinessi, L., Rainero, I., Sorbi, S., Bruni, A., Duara, R., Friedland, R.P., Inzelberg, R., Hampe, W., Bujo, H., Song, Y.Q., Andersen, O.M., Willnow, T.E., Graff-Radford, N., Petersen, R.C., Dickson, D., Der, S.D., Fraser, P.E., Schmitt-Ulms, G., Younkin, S., Mayeux, R., Farrer, L.A., St George-Hyslop, P. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat. Genet. 2007, 39: 168-177.
12. Hardy, J., Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297: 353-356.
13. Maurer, K. The history of Alois Alzheimer's first case Auguste D. In Alzheimer: 100 Years and Beyond, Jucker, M., Beyreuher, K., Haass, C., Nitsch, R., Christen, Y., Fondation IPSEN, eds. (New York: Springer-Verlag Berlin Heidelberg), 2006, 15-36.
14. Morris, J.C., Heyman, A., Mohs, R.C., Hughes, J.P., van Belle, G., Fillenbaum, G., Mellits, E.D., Clark, C. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989, 39: 1159-1165.
15. Braak, H., Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82: 239-259.
16. Palmer, A.M., Gershon, S. Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic? FASEB J. 1990, 4: 2745-2752.
17. Mesulam, M.M. Some cholinergic themes related to Alzheimer's disease: Synaptology of the nucleus basalis, location of m2 receptors, interactions with amyloid metabolism, and perturbations of cortical plasticity. J. Physiol. Paris 1998, 92: 293-298.
18. Braak, H., de Vos, R.A., Jansen, E.N., Bratzke, H., Braak, E. Neuropathological hallmarks of Alzheimer's and Parkinson's diseases. Prog. Brain Res. 1998, 117: 267-285.
19. Selkoe, D.J. Alzheimer's disease is a synaptic failure. Science 2002, 298: 789-791.
20. Giannakopoulos, P., Hof, P.R., Surini, M., Michel, J.P., Bouras, C. Quantitative immunohistochemical analysis of the distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of nonagenarians and centenarians. Acta Neuropathol. 1993, 85: 602-610.
21. Delaere, P., He, Y., Fayet, G., Duyckaerts, C., Hauw, J.J. Beta A4 deposits are constant in the brain of the oldest old: an immunocytochemical study of 20 French centenarians. Neurobiol. Aging 1993, 14: 191-194.
22. Price, J.L., Morris, J.C. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann. Neurol. 1999, 45: 358-368.
23. Guillozet, A.L., Weintraub, S., Mash, D.C., Mesulam, M.M. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch. Neurol. 2003, 60: 729-736.
24. Price, J.L., Mckeel, D.W., Morris, J.C. Synaptic loss and pathological change in older adults - aging versus disease? Neurobiol. Aging 2001, 22: 351-352.
25. Imhof, A., Kovari, E., von Gunten, A., Gold, G., Rivara, C.B., Herrmann, F.R., Hof, P.R., Bouras, C., Giannakopoulos, P. Morphological substrates of cognitive decline in nonagenarians and centenarians: a new paradigm? J. Neurol. Sci. 2007, 257: 72-79.
26. Mesulam, M.M. Principles of Behavior and Cognitive Neurology. Mesulam M.-M. Ed, Oxford University Press, Oxford, UK, 2000, Chap 10.
27. Cummings, J.L., Doody, R., Clark, C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology 2007, 69: 1622-1634.
28. Cummings, J.L. Treatment of Alzheimer's disease: the role of symptomatic agents in an era of disease-modifying therapies. Rev. Neurol. Dis. 2007, 4: 57-62.
29. Glenner, G.G., Wong, C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 1984, 120: 885-890.
30. Kosik, K.S., Joachim, C.L., Selkoe, D.J. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc. Natl. Acad. Sci. USA 1986, 83: 4044-4048.
31. Grundke-Iqbal, I., Iqbal, K., Quinlan, M., Tung, Y.C., Zaidi, M.S., Wisniewski, H.M. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J. Biol. Chem. 1986, 261: 6084-6089.
32. Wood, J.G., Mirra, S.S., Pollock, N.J., Binder, L.I. Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (tau). Proc. Natl. Acad. Sci. USA 1986, 83: 4040-4043.
33. Skovronsky, D.M., Lee, V.M., Trojanowski, J.Q. Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. Annu. Rev. Pathol. 2006, 1: 151-170.
34. Weldon, D.T., Rogers, S.D., Ghilardi, J.R., Finke, M.P., Cleary, J.P., O'Hare, E., Esler, W.P., Maggio, J.E., Mantyh, P.W. Fibrillar beta-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. J. Neurosci. 1998, 18: 2161-2173.
35. Golde, T.E., Eckman, C.B., Younkin S.G. Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochim.. Biophys. Acta 2000, 1502: 172-187.
36. Yankner, B.A., Dawes, L.R., Fisher, S., Villa-Komaroff, L., Oster-Granite, M.L., Neve, R.L. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science 1989, 245: 417-420.
37. Meda, L., Cassatella, M.A., Szendrei, G.I., Otvos, L., Jr., Baron, P., Villalba, M., Ferrari, D., Rossi, F. Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature 1995, 374: 647-650.
38. Lorenzo, A., Yankner, B.A. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc. Natl. Acad. Sci. USA 1994, 91: 12243-12247.
39. Buscigho, J., Lorenzo, A., Yeh, J., Yankner, B.A. beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 1995, 14: 879-888.
40. Lambert, M.P., Stevens, G., Sabo, S., Barber, K., Wang, G., Wade, W., Krafft, G., Snyder, S., Holzman, T.F., Klein, W.L. Beta/A4-evoked degeneration of differentiated SH-SY5Y human neuroblastoma cells. J. Neurosci. Res. 1994, 39: 377-385.
41. Yamaguchi, H., Sugihara, S., Ogawa, A., Oshima, N., Ihara, Y. Alzheimer beta amyloid deposition enhanced by apoE epsilon4 gene precedes neurofibrillary pathology in the frontal association cortex of nondemented senior subjects. J. Neuropathol. Exp. Neurol. 2001, 60: 731-739.
42. Oddo, S., Caccamo, A., Tran, L., Lambert, M.P., Glabe, C.G., Klein, W.L., LaFerla, F.M. Temporal profile of amyloid-beta (Abeta) oligomenzation in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J. Biol. Chem. 2006, 281: 1599-1604.
43. Haass, C., Schlossmacher, M.G., Hung, A.Y., Vigo-Pelfrey, C., Mellon, A., Lieberburg, I., Koo, E.H., Schenk, D., Teplow, D.B., Selkoe, D.J. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 1992, 359: 322-325.
44. Nunan, J., Small, D.H. Regulation ofAPP cleavage by alpha-, beta-and gamma-secretases. FEBS Lett. 2000, 483: 6-10.
45. Selkoe, D., Kopan, R. Notch and Presenilin: Regulated intramembrane proteolysis links development and degeneration. Annu. Rev. Neurosci. 2003, 26: 565-597.
46. Vassar, R. beta-Secretase, APP and A beta in Alzheimer's disease. Subcell. Biochem. 2005, 38: 79-103.
47. Kaether, C., Schmitt, S., Willem, M., Haass, C. Amyloid precursor protein and Notch intracellular domains are generated after transport of their precursors to the cell surface. Traffic 2006 7: 408-415.
48. Wild-Bode, C., Yamazaki, T., Capell, A., Lermer, U., Steiner, H., Ihara, Y., Haass, C. Intracellular generation and accumulation of amyloid beta-peptide terminating at amino acid 42. J. Biol. Chem. 1997, 272: 16085-16088.
49. Tienari, P.J., Ida, N., Ikonen, E., Simons, M., Weidemann, A., Multhaup, G., Masters, C.L., Dotti, C.G., Beyreuther, K. Intracellular and secreted Alzheimer beta-amyloid species are generated by distinct mechanisms in cultured hippocampal neurons. Proc. Natl. Acad. Sci. USA 1997, 94: 4125-4130.
50. Takahashi, R.H., Milner, T.A., Li, F., Nam, E.E., Edgar, M.A., Yamaguchi, H., Beal, M.F., Xu, H.X., Greengard, P., Gouras, G.K. Intraneuronal Alzheimer A beta 42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am. J. Pathol. 2002, 161: 1869-1879.
51. Hartley, D.M., Walsh, D.M., Ye, C.P., Diehl, T., Vasquez, S., Vassilev, P.M., Teplow, D.B., Selkoe, D.J. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 1999, 19: 8876-8884.
52. Klein, W.L. Aβ toxicity in Alzheimer's Disease. In Molecular Mechanisms of Neurodegenerative Diseases, Chesselet MF, ed. (Los Angeles: Humana Press), 2000, 1:1-47.
53. Walsh, D.M., Klyubin, I., Fadeeva, J.V., Rowan, M.J., Selkoe, D.J. Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem. Soc. Trans. 2002, 30: 552-557.
54. Walsh, D.M., Selkoe, D.J. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept. Lett. 2004, 11: 213-228.
55. Klein, W.L. Cytotoxic intermediates in the fibrillation pathway: Abeta oligomers in Alzheimer's disease as a case study. In Protein Misfolding, Aggregation, and Conformational Diseases, Uversky V., ed. (New York: Kluwer Academic/Plenum), 2005, 4: 60-81.
56. Walsh, D.M., Selkoe, D.J. Abeta oligomers - a decade of discovery. J. Neurochem. 2007, 101: 1172-1184.
57. De Stropper, B., Annaert, W., Cupers, P., Saftig, P., Craessaerts, K., Mumm, J.S., Schroeter, E.H., Schrijvers, V., Wolfe, M.S., Ray, W.J., Goate, A., Kopan, R. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 1999, 398: 518-522.
58. Ni, C.Y., Murphy, M.P., Golde, T.E., Carpenter, G. gamma - Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 2001, 294: 2179-2181.
59. Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., Sisodia, S., Malinow, R. APP processing and synaptic function. Neuron 2003, 37: 925-937.
60. Younkin, S.G. Evidence that A beta 42 is the real culprit in Alzheimer's disease. Ann. Neurol. 1995, 37: 287-288.
61. Bitan, G., Kirkitadze, M.D., Lomakin, A., Vollers, S.S., Benedek, G.B., Teplow, D.B. Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through district pathways. Proc. Natl. Acad. Sci. USA 2003, 100: 330-335.
62. Necula, M., Kayed, R., Milton, S., Glabe, C.G. Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J. Biol. Chem. 2007, 282: 10311-10324.
63. Masters, C.L., Simms, G., Weinman, N.A., Multhaup, G., McDonald, B.L., Beyreuther, K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. USA 1985, 82: 4245-4249.
64. Hardy, J.A., Higgins, G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256: 184-185.
65. Mattson, M.P. Pathways towards and away from Alzhermer's disease. Nature 2004, 430: 631-639.
66. Butterfield, D.A. Amyloid beta-peptide [1-42]-associated free radical-induced oxidative stress and neurodegeneration in Alzheimer's disease grain: Mechanisms and consequences. Curr. Med. Chem. 2003, 10: 2651-2659.
67. Schubert, D., Behl, C., Lesley, R., Brack, A., Dargusch, R., Sagara, Y., Kimura, H. Amyloid peptides are toxic via a common oxidative mechanism. Proc. Natl. Acad. Sci. USA 1995, 92: 1989-1993.
68. Behl, C. Amyloid beta-protein toxicity and oxidative stress in Alzheimer's disease. Cell Tissue Res. 1997, 290: 471-480.
69. Pike, C.J., Cummings, B.J., Monzavi, R., Cotman, C.W. Beta-amyloid-induced changes in cultured astrocytes parallel reactive astrocytosis associated with senile plaques in Alzheimer's disease. Neuroscience 1994, 63: 517-531.
70. St George-Hyslop, P.H. Molecular genetics of Alzheimer's disease. Biol. Psychiatry 2000, 47: 183-199.
71. Tanzi, R.E., Bertram, L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 2005, 120: 545-555.
72. Berezovska, O., Lleo, A., Herl, L.D., Frosch, M.P., Stern, E.A., Bacskai, B.J., Hyman, B.T. Familial Alzheimer's disease presenilin 1 mutations cause alterations in the conformation of presenilin and interactions with amyloid precursor protein. J. Neurosci. 2005, 25: 3009-3017.
73. Borchelt, D.R., Ratovitski, T., van L.J., Lee, M.K., Gonzales, V., Jenkins, N.A., Copeland, N.G., Price, D.L., Sisodia, S.S. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 1997, 19: 939-945.
74. Games, D., Adams, D., Alessandrini, R., Barbour, R., Berthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., Guido, T., Hagopian, S., Johnson-Wood, K., Khan, K., Lee, M., Leibowitz, P., Lieberburg, I., Little, S., Masliah, E., McConlogue, L., Montoya-Zavala, M., Mucke, L., Paganini, L., Penniman, E., Power, M., Schenk, D., Seubert, P., Snyder, B., Soriano, F., Tan, H., Vitale, J., Wadsworth, S., Wolozin, B., Zhao, J. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995, 373: 523-527.
75. Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., Cole, G. Correlative memory deficits, Ab elevation, and amyloid plaques in transgenic mice. Science 1996, 274: 99-102.
76. Spires, T.L., Hyman, B.T. Transgenic models of Alzheimer's disease: learning from animals. NeuroRx 2005, 2: 423-437.
77. McGowan, E., Eriksen, J., Hutton, M. A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet. 2006, 22: 281-289.
78. Van Dam, D., De Deyn, P.P. Drug discovery in dementia: the role of rodent models. Nat. Rev. Drug Discov. 2006, 5: 956-970.
79. Eriksen, J.L., Janus, C.G. Plaques, tangles, and memory loss in mouse models of neurodegeneration. Behav. Genet. 2007, 37: 79-100.
80. Duyckaerts, C., Potier, M.C., Delatour, B. Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol. 2008, 115: 5-38.
81. Hsiao, K. Transgenic mice expressing Alzheimer amyloid precursor proteins. Exp. Gerontol. 1998, 33: 883-889.
82. Dodart, J.C., Mathis, C., Bales, K.R., Paul, S.M., Ungerer, A. Early regional cerebral glucose hypometabolism in transgenic mice overexpressing the V717F beta-amyloid precursor protein. Neurosci. Lett. 1999, 277: 49-52.
83. King, D.L., Arendash, G.W., Crawford, F., Sterk, T., Menendez, J., Mullan, M.J. Progressive and gender-dependent cognitive impairment in the APP(SW) transgenic mouse model for Alzheimer's disease. Behav. Brain Res. 1999, 103: 145-162.
84. Chen, G., Chen, K.S., Knox, J., Inglis, J., Bernard, A., Martin, S.J., Justice, A., McConlogue, L., Games, D., Freedman, S.B., Morris, R.G.M. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature 2000, 408: 975-979.
85. Gordon, M.N., King, D.L., Diamond, D.M., Jantzen, P.T., Boyett, K.V., Hope, C.E., Hatcher, J.M., DiCarlo, G., Gottschall, W.P.E., Morgan, D., Arendash, G.W. Correlation between cognitive deficits and A beta deposits in transgenic APP+PS1 mice. Neurobiol. Aging 2001, 22: 377-385.
86. Oddo, S., Caccamo, A., Shepherd, J.D., Murphy, M.P., Golde, T.E., Kayed, R., Metherate, R., Mattson, M.P., Akbari, Y., LaFerla, F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003, 39: 409-421.
87. Casas, C., Sergeant, N., Iiter, J.M., Blanchard, V., Wirths, O., van der K.N., Vingtdeux, V., van de Steeq, E., Ret, G., Canton, T., Drobecq, H., Clark, A., Bonici, B., Delacourte, A., Benavides, J., Schmitz, C., Tremp, G., Bayer, T.A., Benoit, P., Pradier, L. Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Am. J. Pathol. 2004, 165: 1289-1300.
88. Oakley, H., Cole, S.L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., Berry, R., Vassar, R. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzhermer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 2006, 26: 10129-10140.
89. Katzman, R., Terry, R., DeTeresa, R., Brown, T., Davies, P., Fuld, P., Renbing, X., Peck, A. Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann. Neurol. 1988, 23: 138-144.
90. Terry, R.D., Masliah, E., Salmon, D.P., Butters, N., DeTeresa, R., Hill, R., Hansen, L.A., Katzman, R. Physical basis of cognitive alterations in Alzhermer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 1991, 30: 572-580.
91. Blessed, G., Tomlinson, B.E., Roth, M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br. J. Psychiatry 1968, 114: 797-811.
92. Dickson, D.W., Crystal, H.A., Bevona, C., Honer, W., Vincent, I., Davies, P. Correlations of synaptic and pathological markers with cognition ofthe elderly. Neurobiol. Aging 1995, 16: 285-298.
93. Mckee, A.C., Kosik, K.S., Kowall, N.W. Neuritic pathology and dementia in Alzheimer's disease. Ann. Neurol. 1991, 30: 156-165.
94. Arriagada, P.V., Growdon, J.H., Hedley-Whyte, E.T., Hyman, B.T. Neurofibrillary tangles but not senile plaques parallel duration and severity ofAlzheimefs disease. Neurology 1992, 42: 631-639.
95. Berg, L., McKeel, D.W., Jr., Miller, J.P., Baty, J., Morris, J.C. Neuropathological indexes of Alzhermer's disease in demented and nondemented persons aged 80 years and older. Arch. Neurol. 1993, 50: 349-358.
96. Cummings, B.J., Pike, C.J., Shankle, R., Cotman, C.W. beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. Neurobiol. Aging 1996, 17: 921-933.
97. Davies, C.A., Mann, D.M.A., Sumpter, P.Q., Yates, P.O. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's Disease. J. Neurol. Sci. 1987, 78: 151-164.
98. Dodart, J.C., Bales, K.R., Gannon, K.S., Greene, S.J., DeMattos, R.B., Mathis, C., DeLong, C.A., Wu, S., Wu, X., Holtzman, D.M., Paul, S.M. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 2002, 5: 452-457.
99. Kotilinek, L.A., Bacskai, B., Westerman, M., Kawarabayashi, T., Younkin, L., Hyman, B.T., Younkin, S., Ashe, K.H. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci. 2002, 22: 6331-6335.
100. Oda, T., Wals, P., Osterburg, H.H., Johnson, S.A., Pasinetti, G.M., Morgan, T.E., Rozovsky, I., Stine, W.B., Snyder, S.W., Holzman, T.F. Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress. Exp. Neurol. 1995, 136: 22-31.
101. Lambert, M.P., Barlow, A.K., Chromy, B.A., Edwards, C., Freed, R., Liosatos, M., Morgan, T.E., Rozovsky, I., Trommer, B., Viola, K.L., Wals, P., Zhanq, C., Finch, C.E., Krafft, G.A., Klein, W.L. Diffusible, nonfibrillar ligands derived from Abetal-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA 1998, 95: 6448-6453.
102. Lambert, M.P., Viola, K.L., Chromy, B.A., Chang, L., Morgan, T.E., Yu, J., Venton, D.L., Krafft, G.A., Finch, C.E., Klein, W.L. Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J. Neurochem. 2001, 79: 595-605.
103. Klein, W.L., Krafft, G.A., Finch, C.E. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci. 2001, 24: 219-224.
104. Chromy, B.A., Nowak, R.J., Lambert, M.P., Viola, K.L., Chang, L., Velasco, P.T., Jones, B.W., Fernandez, S.J., Lacor, P.N., Horowitz, P., Finch, C.E., Krafft, G.A., Klein, W.L. Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry 2003, 42: 12749-12760.
105. Stine, W.B. Jr., Dahlgren, K.N., Krafft, G.A., LaDu, M.J. In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J. Biol. Chem. 2003, 278: 11612-11622.
106. Tabaton, M., Nunzi, M.G., Xue, R., Usiak, M., utilio-Gambetti, L., Gambetti, P. Soluble amyloid beta-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid. Biochem. Biophys. Res. Commun. 1994, 200: 1598-1603.
107. Teller, J.K., Russo, C., DeBusk, L.M., Angelini, G., Zaccheo, D., gna-Bricarelli, F., Scartezzini, P., Bertolini, S., Mann, D.M., Tabaton, M., Gambetti, P. Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome. Nat. Med. 1996, 2: 93-95.
108. Podlisny, M.B., Ostaszewski, B.L., Squazzo, S.L., Koo, E.H., Rydell, R.E., Teplow, D.B., Selkoe, D.J. Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell-culture. J. Biol. Chem. 1995, 270: 9564-9570.
109. Lue, L.F., Kuo, Y.M., Roher, A.E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J.H., Rydel, R.E., Rogers, J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 1999, 155: 853-862.
110. McLean, C.A., Cherny, R.A., Fraser, F.W., Fuller, S.J., Smith, M.J., Beyreuther, K., Bush, A.I., Masters, C.L. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 1999, 46: 860-866.
111. Naslund, J., Haroutunian, V., Mohs, R., Davis, K.L., Davies, P., Greengard, P., Buxbaum, J.D. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000, 283: 1571-1577.
112. Kirkitadze, M.D., Bitan, G., Teplow, D.B. Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies. J. Neurosci. Res. 2002, 69: 567-577.
113. Walsh, D.M. Selkoe, D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004, 44: 181-193.
114. Klein, W.L., Lacor, P.N., De Felice, E.G., Ferreira, S.T. Molecules that disrupt memory circuits in Alzheimer's disease: The attack on synapses by Abeta oligomers (ADDLs). In Memories: Molecules and Circuits, Bontempi B, Silva AJ, Christen Y, Fondation IPSEN, eds. (New York: Springer-Verlag Berlin Heidelberg), 2007, 155-179.
115. Klein, W.L., De Felice, F.G., Lacor, P.N., Lambert, M.P., Zhao, W.-Q. Why Alzheimee's is a Disease of Memory: Synaptic Targeting by Pathogenic Aβ Oligomers (ADDLs). In Synaptic Plasticity and the Mechanism of Alzheimer's Disease, Selkoe DJ, Triller A, Christen Y, Fondation IPSEN, eds. (New York: Springer-Verlag Berlin Heidelberg), 2008, 103-132.
116. Wang, H.W., Pasternak, J.F., Kuo, H., Ristic, H., Lambert, M.P., Chromy, B., Viola, K.L., Klein, W.L., Stine, W.B., Krafft, G.A., Trommer, B.L. Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 2002, 924: 133-140.
117. Klein, W.L. Synaptic targeting by Aβ oligomers (ADDLs) as a basis for memory loss in early AD. Alzheimer's Dementia 2006, 2: 43-55.
118. Walsh, D.M., Klyubin, I., Fadeeva, J.V., Cullen, WK., Anwyl, R., Wolfe, M.S., Rowan, M.J., Selkoe, D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416: 535-539.
119. Walsh, D.M., Klyubin, I., Cleary, J.P., Townsend, T.M., Shankar, G.M., Podlisny, M.B., Fadeeva, J.V., Anwyl, R., Ashe, K.H., Rowan, M.J., Selkoe, D.J. Natural, cell-derived A beta oligomers: Their production, biological activity and inhibition. Neurobiol. Aging 2004, 25: S161-S162.
120. Chang, L., Bakhos, L., Wang, Z., Venton, D.L., Klein, W.L. Femtomole immunodetection of synthetic and endogenous Amyloid-β oligomers and its application to Alzheimer's Disease drug candidate screening. J. Mol. Neurosci. 2003, 20: 305-313.
121. Gong, Y., Chang, L., Viola, K.L., Lacor, P.N., Lambert, M.P., Finch, C.E., Krafft, G.A., Klein, W.L. Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. USA 2003, 100: 10417-10422.
122. Lacor, P.N., Buniel, M.C., Chang, L., Fernandez, S.J., Gong, Y., Viola, K.L., Lambert, M.P., Velasco, P.T., Bigio, E.H., Finch, C.E., Krafft, G.A., Klein, W.L. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J. Neurosci. 2004, 24: 10191-10200.
123. Lambert, M.P., Velasco, P.T., Chang, L., Viola, K.L., Fernandez, S., Lacor, P.N., Khuon, D., Gong, Y.S., Bigio, E.H., Shaw, P., De Felice, E.G., Krafft, G.A., Klein, W.L. Monoclonal antibodies that target pathological assemblies of A beta. J. Neurochem. 2007, 100: 23-35.
124. Golde, T.E., Dickson, D., Hutton, M. Filling the gaps in the abeta cascade hypothesis of Alzheime'rs disease. Curr. Alzheimer Res. 2006, 3: 421-43.
125. Mamikonyan, G., Necula, M., Mkrtichyan, M., Ghochikyan, A., Petrushina, I., Movsesyan, N., Mina, E., Kiyatkin, A., Glabe, C.G., Cribbs, D.H., Aqadjanyan, M.G. Anti-A beta(1-11) antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. J. Biol. Chem. 2007, 282: 22376-22386.
126. Nicoll, J.A., Wilkinson, D., Holmes, C., Steart, P., Markham, H., Weller, R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 2003, 9: 448-452.
127. Ferrer, I., Boada, R.M., Sanchez Guerra, M.L., Rey, M.J., Costa-Jussa, F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimefs disease. Brain Pathol. 2004, 14: 11-20.
128. Gilman, S., Koller, M., Black, R.S., Jenkins, L., Griffith, S.G., Fox, N.C., Eisner, L., Kirby, L., Rovira, M.B., Foreffe, F., Orqoqozo, J.M., AN1792(QS-21)-201 Study team. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64: 1553-1562.
129. Masliah, E., Hansen, L., Adame, A., Crews, L., Bard, F., Lee, C., Seubert, P., Games, D., Kirby, L., Schenk, D. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 2005, 64: 129-131.
130. Seabrook, G.R., Ray, W.J., Shearman, M., Hutton, M. Beyond amyloid: the next generation of Alzheimer's disease therapeutics. Mol. Interv. 2007, 7: 261-270.
131. Georganopoulou, D.G., Chang, L., Nam, J.M., Thaxton, C.S., Mufson, E.J., Klein, W.L., Mirkin, C.A. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2005, 102: 2273-2276.
132. Scheibel, M.E., Lindsay, R.D., Tomiyasu, U., Scheibel, A.B. Progressive dendritic changes in the aging human limbic system. Exp. Neurol. 1976, 53: 420-430.
133. Sze, C.I., Bi, H., Kleinschmidt-DeMasters, B.K., Filley, C.M., Martin, L.J. Selective regional loss of exocytotic presynaptic vesicle proteins in Alzheimer's disease brains. J. Neurol. Sci. 2000, 175: 81-90.
134. Ginsberg, S.D., Hemby, S.E., Lee, V.M., Eberwine, J.H., Trojanowski, J.Q. Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons. Ann. Neurol. 2000, 48: 77-87.
135. Loring, J.F., Wen, X., Lee, J.M., Seilhamer, J., Somogyi, R. A gene expression profile of Alzheimer's disease. DNA Cell Biol. 2001, 20: 683-695.
136. Colangelo, V., Schurr, J., Ball, M.J., Pelaez, R.P., Bazan, N.G., Lukiw, W.J. Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling. J. Neurosci. Res. 2002, 70: 462-473.
137. Dickey, C.A., Loring, J.F., Montgomery, J., Gordon, M.N., Eastman, P.S., Morgan, D. Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein plus presenilin-1 transgenic mice. J. Neurosci. 2003, 23: 5219-5226.
138. Yao, P.J., Zhu, M., Pyun, E.I., Brooks, A.I., Therianos, S., Meyers, V.E., Coleman, P.D. Defects in expression of genes related to synaptic vesicle trafficking in frontal cortex of Alzheimer's disease. Neurobiol. Dis. 2003, 12: 97-109.
139. Blalock, E.M., Geddes, J.W., Chen, K.C., Porter, N.M., Markesbery, W.R., Landfield, P.W. Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc. Natl. Acad. Sci. USA 2004, 101: 2173-2178.
140. Ginsberg, S.D., Che, S., Counts, S.E., Mufson, E.J. Single cell gene expression profiling in Alzheimer's disease. Neurobiol. 2006, 3: 302-318.
141. Wu, Z.L., Ciallella, J.R., Flood, D.G., O'Kane, T.M., Bozyczko-Coyne, D., Savage, M.J. Comparative analysis of cortical gene expression in mouse models of Alzheimer's disease. Neurobiol. Aging 2006, 27: 377-386.
142. Sorra, K.E. Harris, K.M. Overview on the structure, composition, function, development, and plasticity of hippocampal dendritic spines. Hippocampus 2000, 10: 501-511.
143. Andersen, P., Soleng, A.F. Long-term potentiation and spatial training are both associated with the generation of new excitatory synapses. Brain Res. Brain Res. Rev. 1998, 26: 353-359.
144. Dunaevsky, A., Woolley, C.S. Structural plasticity of dendrites. In Dendrites, Stuart G, Spruston N, Hausser M, eds. (New York: Oxford University Press), 2007, 499-530.
145. Mainen, Z.F., Abbott, L. Functional plasticity at dendritic synapses. In Dendrites, Stuart, G., Spruston, N., Hausser, M., eds. (New York: Oxford University Press), 2007, 465-498.
146. El Hachimi, K.H., Foncin, J.F. Loss of dendritic spines in Alzheimer's disease. C. R. Acad. Sci. III 1990, 311: 397-402.
147. Ferrer, I., Gullotta, F. Downs-Syndrome and Alzheimers-Disease - Dendritic Spine Counts in the Hippocampus. Acta Neuropathol. 1990, 79: 680-685.
148. Sze, C.I., Troncoso, J.C., Kawas, C., Mouton, P., Price, D.L., Martin, L.J. Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J. Neuropath. Exp. Neurol. 1997, 56: 933-944.
149. Bigio, E.H., Hynan, L.S., Sontag, E., Satumtira, S., White, C.L. Synapse loss is greater in presenile than senile onset Alzheimer disease: implications for the cognitive reserve hypothesis. Neuropathol. Appl. Neurobiol. 2002, 28: 218-227.
150. Terry, R.D. Alzheimefs disease and the aging brain. J. Geriatr. Psychiatry Neurol. 2006, 19: 125-128.
151. Masliah, E., Terry, R.D., Mallory, M., Alford, M., Hansen, L.A. Diffuse plaques do not accentuate synapse loss in Alzheimer's Disease. Am. J. Pathol. 1990, 137: 1293-1297.
152. Mucke, L., Masliah, E., Yu, G.Q., Mallory, M., Rockenstern, E.M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., McConlogue, L. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 2000, 20: 4050-4058.
153. Palop, J.J., Chin, J., Mucke, L. A network dysfunction perspective on neurodegenerative diseases. Nature 2006, 443: 768-773.
154. Jacobsen, J.S., Wu, C.C., Redwine, J.M., Comery, T.A., Arias, R., Bowlby, M., Martone, R., Morrison, J.H., Pangalos, M.N., Reinhart, P.H., Bloom, F.E. Early-onset behavioral and synaptic deficits in a mouse model of Alzheime'rs disease. Proc. Natl. Acad. Sci. USA 2006, 103: 5161-5166.
155. Coleman, P.D., Yao, P.J. Synaptic slaughter in Alzheimer's disease. Neurobiol. Aging 2003, 24: 1023-1027.
156. Small, D.H. Mechanisms of synaptic homeostasis in Alzheimer's disease. Curr. Alzheimer Res. 2004, 1: 27-32.
157. Counts, S.E., Nadeem, M., Lad, S.P., Wuu, J., Mufson, E.J. Differential expression of synaptic proteins in the frontal and temporal cortex of elderly subjects with mild cognitive impairment. J. Neuropathol. Exp. Neurol. 2006, 65: 592-601.
158. Bennett, D.A., Schneider, J.A., Bienias, J.L., Evans, D.A., Wilson, R.S. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology 2005, 64: 834-841.
159. Hayashi, K., Ishikawa, R., Ye, L.H., He, X.L., Takata, K., Kohama, K., Shirao, T. Modulatory role of drebrin on the cytoskeleton within dendritic spines in the rat cerebral cortex. J. Neurosci. 1996, 16: 7161-7170.
160. Takahashi, H., Sekino, Y., Tanaka, S., Mizui, T., Kishi, S., Shirao, T. Drebrin-dependent actin clustering in dendritic filopodia governs synaptic targeting of postsynaptic density-95 and dendritic spine morphogenesis. J. Neurosci. 2003, 23: 6586-6595.
161. Shim, K.S., Lubec, G. Drebrin, a dendritic spine protein, is manifold decreased in brains of patients with Alzheimer's disease and Down syndrome. Neurosci. Lett. 2002, 324: 209-212.
162. Hatanpaa, K., Isaacs, K.R., Shirao, T., Brady, D.R., Rapoport, S.I. Loss of proteins regulating synaptic plasticity in normal aging of the human brain and in Alzheimer disease. J. Neuropath. Exp. Neurol. 1999, 58: 637-643.
163. Harigaya, Y., Shoji, M., Shirao, T., Hirai, S. Disappearance of actin-binding protein, drebrin, from hippocampal synapses in Alzheimer's disease. J. Neurosc. Res. 1996, 43: 87-92.
164. Callahan, L.M., Coleman, P.D. Neurons Bearing Neurofibrillary Tangles Are Responsible for Selected Synaptic Deficits in Alzheimers-Disease. Neurobiol. Aging 1995, 16: 311-314.
165. Mukaetova-Ladinska, E.B., Garcia-Siera, F., Hurt, J., Gertz, H.J., Xuereb, J.H., Hills, R., Brayne, C., Huppert, F.A., Paykel, E.S., McGee, M., Jakes, R., Honer, W.G., Harrington, C.R., Wischik, C.M. Staging of cytoskeletal and beta-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease. Am. J. Pathol. 2000, 157: 623-636.
166. DeKosky, S.T., Ikonomovic, M.D., Styren, S.D., Beckett, L., Wisniewski, S., Bennett, D.A., Cochran, E.J., Kordower, J.H., Mufson, E.J. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann. Neurol. 2002, 51: 145-155.
167. Scheff, S.W., Price, D.A. Synaptic pathology in Alzheimer's disease: a review ofultrastructural studies. Neurobiol. Aging 2003, 24: 1029-1046.
168. Geula, C., Mesulam, M.M. Systematic regional variations in the loss of cortical cholinergic fibers in Alzheimer's disease. Cereb. Cortex 1996, 6: 165-177.
169. Bell, K.F., Cuello, A.C. Altered synaptic function in Alzheimer's disease. Eur. J. Pharmacol. 2006, 545: 11-21.
170. Scheff, S.W., Price, D.A. Alzheimer's disease-related alterations in synaptic density: neocortex and hippocampus. J. Alzheimer Dis. 2006, 9: 101-115.
171. Olson, M.I., Shaw, C.M. Presenile dementia and Alzheimer's disease in mongolism. Brain 1969, 92: 147-156.
172. Marin-Padilla, M. Pyramidal cell abnormalities in the motor cortex of a child with Down's syndrome. A Golgi study. J. Comp. Neurol. 1976, 167: 63-81.
173. Fiala, J.C., Spacek, J., Harris, K.M. Dendritic spine pathology: cause or consequence of neurological disorders? Brain Res. Brain Res. Rev. 2002, 39: 29-54.
174. Greber, S., Lubec, G., Cairns, N., Fountoulakis, M. Decreased levels of synaptosomal associated protein 25 in the brain of patients with Down syndrome and Alzheimer's disease. Electrophoresis 1999, 20: 928-934.
175. Lubec, B., Weitzdoerfer, R., Fountoulakis, M. Manifold reduction of moesin in fetal Down syndrome brain. Biochem. Biophys. Res. Commun 2001, 286: 1191-1194.
176. Weitzdoerfer, R., Dierssen, M., Fountoulakis, M., Lubec, G. Fetal life in Down syndrome starts with normal neuronal density but impaired dendritic spines and synaptosomal structure. J. Neural Transm. Suppl. 2001, 61: 59-70.
177. Kleschevnikov, A.M., Belichenko, P.V., Villar, A.J., Epstein, C.J., Malenka, R.C., Mobley, W.C. Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model ofDown syndrome. J. Neurosci. 2004, 24: 8153-8160.
178. Belichenko, P.V., Kleschevnikov, A.M., Salehi, A., Epstein, C.J., Mobley, W.C. Synaptic and cognitive abnormalities in mouse models of Down syndrome: exploring genotype-phenotype relationships. J. Comp. Neurol. 2007, 504: 329-345.
179. Boncristiano, S., Calhoun, M.E., Howard, V., Bondolfi, L., Kaeser, S.A., Wiederhold, K.H., Staufenbiel, M., Jucker, M. Neocortical synaptic bouton number is maintained despite robust amyloid deposition in APP23 transgenic mice. Neurobiol. Aging 2005, 26: 607-613.
180. Almeida, C.G., Tampellini, D., Takahashi, R.H., Greengard, P., Lin, M.T., Snyder, E.M., Gouras, G.K. Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. Neurobiol. Dis. 2005, 20: 187-198.
181. Rutten, B.P., Van der Kolk, N.M., Schafer, S., van Zandvoort, M.A., Bayer, T.A., Steinbusch, H.W., Schmitz, C. Age-related loss of synaptophysin immunoreactive presynaptic boutons within the hippocampus of APP751SL, PS1M146L, and APP751SL/PS1M146L transgenic mice. Am. J. Pathol. 2005, 167: 161-173.
182. Calon, F., Lim, G.P., Yang, F., Morihara, T., Teter, B., Ubeda, O., Rostaing, P., Triller, A., Salem, N., Jr., Ashe, K.H., Frautschy, S.A., Cole, G.M. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 2004, 43: 633-645.
183. Dong, H.X., Martin, M.V., Chambers, S., Csernansky, J.G. Spatial relationship between synapse loss and beta-amyloid deposition in Tg2576 mice. J. Comp. Neurol. 2007, 500: 311-321.
184. Kojima, N., Shirao, T. Synaptic dysfunction and disruption of postsynaptic drebrin-actin complex: A study of neurological disorders accompanied by cognitive deficits. Neurosci. Res. 2007, 58: 1-5.
185. Lanz, T.A., Carter, D.B., Merchant, K.M. Dendritic spine loss in the hippocampus of young PDAPP and Tg2576 mice and its prevention by the ApoE2 genotype. Neurobiol. Dis. 2003, 13: 246-253.
186. Moolman, D.L., Vitolo, O.V., Vonsattel, J.P.G., Shelanski, M.L. Dendrite and dendritic spine alterations in Alzheimer models. J. Neurocytol. 2004, 33: 377-387.
187. Tsai, J., Grutzendler, J., Duff, K., Gan, W.B. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat. Neurosci. 2004, 7: 1181-1183.
188. Spires, T.L., Meyer-Luehmann, M., Stern, E.A., McLean, P.J., Skoch, J., Nguyen, P.T., Bacskai, B.J., Hyman, B.T. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J. Neurosci. 2005, 25: 7278-7287.
189. Strome, E.M., Doudet, D.J. Animal models of neurodegenerative disease: insights from in vivo imaging studies. Mol. Imaging Biol. 2007, 9: 186-195.
190. Dodart, J.C., Mathis, C., Saura, J., Bales, K.R., Paul, S.M., Ungerer, A. Neuroanatomical abnormalities in behaviorally characterized APP(V717F) transgenic mice. Neurobiol. Dis. 2000, 7: 71-85.
191. Dierssen, M., avides-Piccione, R., Martinez-Cue, C., Estivill, X., Florez, J., Elston, G.N., DeFelipe, J. Alterations of neocortical pyramidal cell phenotype in the Ts65Dn mouse model of Down syndrome: effects of environmental enrichment. Cereb. Cortex 2003, 13: 758-764.
192. Hsia, A.Y., Masliah, E., McConlogue, L., Yu, G.Q., Tatsuno, G., Hu, K., Kholodenko, D., Malenka, R.C., Nicoll, R.A., Mucke, L. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl. Acad. Sci. USA 1999, 96: 3228-3233.
193. Alpar, A., Ueberham, U., Bruckner, M.K., Seeger, G., Arendt, T., Gartner, U. Different dendrite and dendritic spine alterations in basal and apical arbors in mutant human amyloid precursor protein transgenic mice. Brain Res., 2006, 1099: 189-198.
194. Le, R., Cruz, L., Urbanc, B., Knowles, R.B., Hsiao-Ashe, K., Duff, K., Irizarry, M.C., Stanley, H.E., Hyman, B.T. Plaque-induced abnormalities in neurite geometry in transgenic models of Alzheimer disease: implications for neural system disruption. J. Neuropathol. Exp. Neurol. 2001, 60: 753-758.
195. Grutzendler, J., Helmin, K., Tsai, J., Gan, W.B. Various dendritic abnormalities are associated with fibrillar amyloid deposits in Alzhermer's disease. Ann. N. Y. Acad. Sci. 2007, 1097: 30-39.
196. Spires-Jones, T.L., Meyer-Luehmann, M., Osetek, J.D., Jones, P.B., Stem, E.A., Bacskai, B.J., Hyman, B.T. Impaired spine stability underlies plaque-related spine loss in an Alzheimer's disease mouse model. Am. J. Pathol. 2007, 171: 1304-1311.
197. Klunk, W.E., Engler, H., Nordberg, A., Bacskai, B.J., Wang, Y., Price, J.C., Bergstrom, M., Hyman, B.T., Langstrom, B., Mathis, C.A. Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography. Neuroimaging Clin. N. Am. 2003, 13: 781-9.
198. Okamura, N., Suemoto, T., Shiomitsu, T., Suzuki, M., Shimadzu, H., Akatsu, H., Yamamoto, T., Arai, H., Sasaki, H., Yanai, K., Staufenbiel, M., Kudo, Y., Sawada, T. A novel imaging probe for in vivo detection of neuritic and diffuse amyloid plaques in the brain. J. Mol. Neurosci. 2004, 24: 247-255.
199. Bacskai, B.J., Frosch, M.P., Freeman, S.H., Raymond, S.B., Augustinack, J.C., Johnson, K.A., Irizarry, M.C., Klunk, W.E., Mathis, C.A., DeKosky, S.T., Greenberg, S.M., Hyman, B.T., Growdon, J.H. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch. Neurol. 2007, 64: 431-434.
200. Maeda, J., Ji, B., Irie, T., Tomiyama, T., Maruyama, M., Okauchi, T., Staufenbiel, M., Iwata, N., Ono, M., Saido, T.C., Suzuki, K., Mori, H., Higuchi, M., Suhara, T. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J. Neurosci. 2007, 27: 10957-10968.
201. Caughey, B., Lansbury, P.T., Jr. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 2003, 26: 267-298.
202. Klein, W.L., Stine, W.B., Teplow, D.B. Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol. Aging 2004, 25: 569-580.
203. Bitan, G., Fradinger, E.A., Spring, S.M., Teplow, D.B. Neurotoxic protein oligomers - what you see is not always what you get. Amyloid 2005, 12: 88-95.
204. Teplow, D.B., Lazo, N.D., Bitan, G., Bernstein, S., Wyttenbach, T., Bowers, M.T., Baumketner, A., Shea, J.E., Urbanc, B., Cruz, L., Borreguero, J., Stanley, H.E. Elucidating amyloid beta-protein folding and assembly: A multidisciplinary approach. Acc. Chem. Res. 2006, 39: 635-645.
205. Bitan, G. Structural study of metastable amyloidogenic protein oligomers by photo-induced cross-linking of unmodified protiens. Methods Enzymol. 2006, 413: 217-236.
206. Kayed, R., Head, E., Thompson, J.L., McIntire, T.M., Milton, S.C., Colman, C.W., Glabe, C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300: 486-489.
207. Haass, C. Selkoe, D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 2007, 8: 101-112.
208. Hepler, R.W., Grimm, K.M., Nahas, D.D., Breese, R., Dodson, E.C., Acton, P., Keller, P.M., Yeager, M., Wang, H., Shughrue, P., Kinney, G., Joyce, J.G. Solution state characterization of amyloid beta-derived diffusible ligands. Biochemistry 2006, 45: 15157-15167.
209. Barghom, S., Nimmrich, V., Striebinger, A., Krantz, C., Keller, P., Janson, B., Bahr, M., Schmidt, M., Bitner, R.S., Harlan, J., Barlow, E., Ebert, U., Hillen, H. Globular amyloid beta-peptide(1-42) oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. J. Neurochem. 2005, 95: 834-847.
210. Glabe, C. Common structure and mechanism of amyloid pathogenesis in degenerative diseases. Biophys. J. 2004, 86: 23A.
211. Lesne, S., Koh, M.T., Kotilinek, L., Kayed, R., Glabe, C.G., Yang, A., Gallagher, M., Ashe, K.H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440: 352-357.
212. Dahlgren, K.N., Manelli, A.M., Stine, W.B., Baker, L.K., Krafft, G.A., LaDu, M.J. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J. Biol. Chem. 2002, 277: 32046-32053.
213. Hoshi, M., Sato, M., Matsumoto, S., Noguchi, A., Yasmake, K., Yoshida, N., Sato, K. Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase 1/glycogen synthase kinase-3beta. Proc. Natl. Acad. Sci. USA 2003, 100: 6370-6375.
214. Lashuel, H.A., Hartley, D., Petre, B.M., Walz, T., Lansbury, P.T., Jr. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 2002, 418: 291.
215. Harper, J.D., Wong, S.S., Lieber, C.M., Lansbury, P.T. Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chem. Biol. 1997, 4: 119-125.
216. Burdick, D., Soreghan, B., Kwon, M., Kosmoski, J., Knauer, M., Henschen, A., Yates, J., Colman, C., Glabe, C. Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs. J. Biol. Chem. 1992, 267: 546-554.
217. Jarrett, J.T., Berger, E.P., Lansbury, P.T., Jr. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993, 32: 4693-4697.
218. Teplow, D.B. Structural and kinetic features of amyloid betaprotein fibrillogenesis. Amyloid. 1998, 5: 121-142.
219. Roher, A.E., Lowenson, J.D., Clarke, S., Woods, A.S., Cotter, R.J., Gowing, E., Ball, MJ. beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc. Natl. Acad. Sci. USA 1993, 90: 10836-10840.
220. Roher, A.E., Palmer, K.C., Yurewicz, E.C., Ball, M.J., Greenberg, B.D. Morphological and biochemical analyses of amyloid plaque core proteins purified from Alzheimer disease brain tissue. J. Neurochem. 1993, 61: 1916-1926.
221. Kuo, Y.-M., Emmerlings, M.R., Vigo-Pelfrey, C., Kasunic, T.C., Kirkpatrick, J.B., Murdoch, G.H., Ball, M.J., Roher, A. Water soluble Ab (N40, N42) oligomers in normal and Alzheimer disease brains. J. Biol. Chem. 1996, 271: 4077-4081.
222. Frackowiak, J., Zoltowska, A., Wisniewski, H.M. Non-fibrillar beta-amyloid protein is associated with smooth muscle cells of vessel walls in Alzheimer disease. J. Neuropathol. Exp. Neurol. 1994, 53: 637-645.
223. Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., Ihara, Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 1994, 13: 45-53.
224. Gravina, S.A., Ho, L., Eckman, C.B., Long, K.E., Otvos, L., Jr., Younkin, L.H., Suzuki, N., Younkin, S.G. Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J. Biol. Chem. 1995, 270: 7013-7016.
225. Roher, A.E., Chaney, M.O., Kuo, Y.M., Webster, S.D., Stine, W.B., Haverkamp, L.J., Woods, A.S., Cotter, R.J., Tuohy, J.M., Krafft, G.A., Bonnell, B.S., Emmerling, M.R. Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J. Biol. Chem. 1996, 271: 20631-20635.
226. Lacor, P.N., Buniel, M.C., Furlow, P.W., Clemente, A.S., Velasco, P.T., Wood, M., Viola, K.L., Klein, W.L. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J. Neurosci. 2007, 27: 796-807.
227. Cheng, I.H., Scearce-Levie, K., Legleiter, J., Palop, J.J., Gerstein, H., Bien-Ly, N., Puolivali, J., Lesne, S., Ashe, K.H., Muchowski, P.J., Mucke, L. Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J. Biol. Chem. 2007, 282: 23818-23828.
228. Kovacs, G.G., Head, M.W., Hegyi, I., Bunn, T.J., Flicker, H., Hainfellner, J.A., McCardle, L., Laszlo, L., Jarius, C., Ironside, J.W., Budka, H. Immunohistochemistry for the prion protein: comparison of different monoclonal antibodies in human prion disease subtypes. Brain Pathol. 2002, 12: 1 -11.
229. DeKosky, S.T., Abrahamson, E.E., Ciallella, J.R., Paljug, W.R., Wisniewski, S.R., Clark, R.S., Ikonomovic, M.D. Association of increased cortical soluble abeta42 levels with diffuse plaques after severe brain injury in humans. Arch. Neurol. 2007, 64: 541-544.
230. Vakil, E. The effect of moderate to severe traumatic brain injury (TBI) on different aspects of memory: a selective review. J Clin. Exp. Neuropsychol. 2005, 27: 977-1021.
231. Ohno, M., Chang, L., Tseng, W., Oakley, H., Citron, M., Klein, W.L., Vassar, R., Disterhoft, J.F. Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1. Eur. J. Neurosci. 2006, 23: 251-260.
232. Xia, W.M., Zhang, J.M., Kholodenko, D., Citron, M., Podlisny, M.B., Teplow, D.B., Haass, C., Seubert, P., Koo, E.H., Selkoe, D.J. Enhanced production and oligomerization of the 42-residue amyloid beta-protein by Chinese hamster ovary cells stably expressing mutant presenilins. J. Biol. Chem. 1997, 272: 7977-7982.
233. Walsh, D.M., Tseng, B.P., Rydel, R.E., Podlisny, M.B., Selkoe, D.J. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry 2000, 39: 10831-10839.
234. Wang, Q., Walsh, D.M., Rowan, M.J., Selkoe, D.J., Anwyl, R. Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J. Neurosci. 2004, 24: 3370-3378.
235. Rowan, M.J., Klyubin, I., Wang, Q., Hu, N.W., Anwyl, R. Synaptic memory mechanisms: Alzheimer's disease amyloid beta-peptide-induced dysfunction. Biochem. Soc. Trans. 2007, 35: 1219-1223.
236. Larson, J., Lynch, G., Games, D., Seubert, P. Alterations in synaptic transmission and long-term potentiation in hippocampal slices from young and aged PDAPP mice. Brain Res. 1999, 840: 23-35.
237. Buttini, M., Yu, G.Q., Shockley, K., Huang, Y.D., Jones, B., Masliah, E., Mallory, M., Yeo, T., Longo, F.M., Mucke, L. Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation. J. Neurosci. 2002, 22: 10539-10548.
238. Van Dam, D., D'Hooge, R., Staufenbiel, M., Van Ginneken, C., Van Meir, F., De Deyn, P.P. Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur. J. Neurosci. 2003, 17: 388-396.
239. Cleary, J.P., Walsh, D.M., Holmeister, J.J., Shankar, G.M., Kuskowski, M.A., Selkoe, D.J., Ashe, K.H. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 2005, 8: 79-84.
240. Lee, E.B., Leng, L.Z., Zhang, B., Kwong, L., Trojanowski, J.Q., Abel, T., Lee, V.M.Y. Targeting amyloid-beta peptide (A beta) oligomers by passive immunization with a conformation- selective monoclonal antibody improves learning and memory in A beta precursor protein (APP) transgenic mice. J. Biol. Chem. 2006, 281: 4292-4299.
241. Klyubin, I., Walsh, D.M., Lemere, C.A., Cullen, WK., Shankar, G.M., Betts, V., Spooner, E.T., Jiang, L., Anwyl, R., Selkoe, D.J., Rowan, M.J. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat. Med. 2005, 11: 556-561.
242. Townsend, M., Shankar, G.M., Mehta, T., Walsh, D.M., Selkoe, D.J. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J. Physiol. 2006, 572: 477-492.
243. Deshpande, A., Mina, E., Glabe, C., Buscigho, J. Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J. Neurosci. 2006, 26: 6011-6018.
244. Calabrese, B., Shaked, G.M., Tabarean, I.V., Braga, J., Koo, E.H., Halpain, S. Rapid, concurrent alterations in pre- and postsynaptic structure induced by naturally-secreted amyloid-beta protein. Mol. Cell Neurosci. 2007, 35: 183-193.
245. Gouras, G.K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J.P., Haroutunian, V., Buxbaum, J.D., Xu, H., Greengard, P., Relkin, N.R. Intraneuronal Abeta42 accumulation in human brain. Am. J. Pathol. 2000, 156: 15-20.
246. Tseng, B.P., Kitazawa, M., LaFerla, F.M. Amyloid beta-peptide: the inside story. Curr. Alzheimer Res. 2004, 1: 231-239.
247. Verdier, Y., Zarandi, M., Penke, B. Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease. J. Pept. Sci. 2004, 10: 229-248.
248. Kim, E., Sheng, M. PDZ domain proteins of synapses. Nat. Rev. Neurosci. 2004, 5: 771-781.
249. Lacor, P.N., Viola, K.L., Lambert, M.P., Finch, C.E., Krafft, G.A., Klein, W.L. 2002. Synapse homeostasis, its disruption by soluble Aβ oligomers, and reversal of memory loss in Alzheimer's disease. Program No 751.7. 2002 Abstract Viewer/Itinerary Planner, Washington DC: Society for Neuroscience.
250. Lacor, P.N., Buniel, M.C., Cain, P.C., Chang, L., Lambert, M.P., Klein, W.L. Synaptic targeting by Alzheimer's related Abeta oligomers. Neurobiol. Aging 2004, 25(S2):S446.
251. Sanz Clemente, A., Lacor, P.N., Gong, Y., Velasco, P.T., Khuon, D., Klein, W.L. 2005. ADDL binding at synapses is associated with the post-synaptic density complex. Program No 422.14. 2005 Abstract Viewer/Itinerary Planner, Washington DC: Society for Neuroscience.
252. Gouras, G.K., Almeida, C.G., Takahashi, R.H. Intraneuronal Abeta accumulation and origin of plaques in Alzheimer's disease. Neurobiol Aging 2005, 26: 123 5-1244.
253. LaFerla, F.M., Green, K.N., Oddo, S. Intracellular amyloid-beta in Alzheimer's disease. Nat. Rev. Neurosci. 207, 8: 499-509.
254. Tampellini, D., Magrane, J., Takahashi, R.H., Li, F., Lin, M.T., Almeida, C.G., Gouras, G.K. Internalized antibodies to the A beta domain of APP reduce neuronal A beta and protect against synaptic alterations. J. Biol. Chem. 2007, 282: 18895-18906.
255. Oddo, S., Caccamo, A., Smith, I.E., Green, K.N., LaFerla, F.M. A dynamic relationship between intracellular and extracellular pools of Abeta. Am. J. Pathol. 2006, 168: 184-194.
256. Wirths, O., Multhaup, G., Bayer, T.A. A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide - the first step of a fatal cascade. J. Neurochem. 2004, 91: 513-520.
257. Mesulam, M.M. Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles. Neuron 1999, 24: 521-529.
258. Lacor, P.N., Buniel, M.C., Klein, W.L. 2004. ADDLs (Aβ oligomers) alter structure and function of synaptic spines. Program No 218.3. 2004 Abstract Viewer/Itinerary Planner, Washington DC: Society for Neuroscience.
259. Lacor, P.N., Sanz Clemente, A., Viola, K.L., Klein, W.L. 2005. Changes in NMDA receptor subunit 1 and 2B expression in ADDL-treated hippocampal neurons. Program No 786.17. 2005 Abstract Viewer/ Itinerary Planner, Washington DC: Society for Neuroscience.
260. Lacor, PN, Viola, KL, Velasco, P, Bigio, E, Klein, WL. 2003. Targeting of synapes and memory-linked IEG protein ARC by ADDLs. Program No 945.14. 2003 Abstract Viewer/Itinerary Planner, Washington DC: Society for Neuroscience.
261. Guzowski, J.F. Insights into immediate-early gene function in hippocampal memory consolidation using antisense oligonucleotide and fluorescent imaging approaches. Hippocampus 2002, 12: 86-104.
262. Kelly, M.P. Deadwyler, S.A. Experience-dependent regulation of the immediate-early gene arc differs across brain regions. J. Neurosci. 2003, 23: 6443-6451.
263. Zhao, W.Q., De Felice, F.G., Fernandez, S., Chen, H., Lambert, M.P., Quon, M.J., Krafft, G.A., Klein, W.L. Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J. 2008, 22: 246-60.
264. Roselli, F., Tirard, M., Lu, J., Hutzler, P., Lamberti, P., Livrea, P., Morabito, M., Almeida, O.F.X. Soluble beta-amyloid(1-40) induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses. J. Neurosci. 2005, 25: 11061-11070.
265. Snyder, E.M., Nong, Y., Almeida, C.G., Paul, S., Moran, T., Choi, E.Y., Naim, A.C., Salter, M.W., Lombroso, P.J., Gouras, G.K., Greengard, P. Regulation of NMDA receptor trafficking by amyloid-beta. Nat. Neurosci. 2005, 8: 1051-1058.
266. Hsieh, H., Boehm, J., Sato, C., Iwatsubo, T., Tomita, T., Sisodia, S., Malinow, R. AMPAR removal underlies A beta-induced synaptic depression and dendritic spine loss. Neuron 2006, 52: 831-843.
267. Chang, E.H., Savage, M.J., Flood, D.G., Thomas, J.M., Levy, R.B., Mahadomrongkul, V., Shirao, T., Aoki, C., Huerta, P.T. AMPA receptor downscaling at the onset of Alzheimer's disease pathology in double knockin mice. Proc. Natl. Acad. Sci. USA 2006, 103: 3410-3415.
268. Scheff, S. Reactive synaptogenesis in aging and Alzheimer's disease: Lessons learned in the Colman laboratory. Neurochem. Res. 2003, 28: 1625-1630.
269. De Felice, F.G., Wu, D., Lambert, M.P., Fernandez, S.J., Velasco, P.T., Lacor, P.N., Bigio, E.H., Jerecic, J., Acton, P.J., Shughrue, P.J., Chen-Dodson, E., Kinney, G.G., Klein, W.L. Alzheimer's disease-type tau hyperphosphorylation in hippocampal neurons induced by AP oligomers. 2007, [Epub ahead of print].
270. Rapoport, M., Dawson, H.N., Binder, L.I., Vitek, M.P., Ferreira, A. Tau is essential to beta -amyloid-induced neurotoxicity. Proc. Natl. Acad. Sci. USA 2002, 99: 6364-6369.
271. Gamblin, T.C., Chen, F., Zambrano, A., Abraha, A., Lagalwar, S., Guillozet, A.L., Lu, M., Fu, Y., Garcia-Sierra, F., LaPointe, N., Miller, R., Berry, R.W., Binder, L.I., Cryns, V.L. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2003, 100: 10032-10037.
272. Chong, Y.H., Shin, Y.J., Lee, E.O., Kayed, R., Glabe, C.G., Tenner, A.J. ERK1/2 activation mediates A beta oligomer-induced neurotoxicity via caspase-3 activation and tau cleavage in rat organotypic hippocampal slice cultures. J. Biol. Chem. 2006, 281: 20315-20325.
273. Gotz, J., Chen, F., van Dorpe, J., Nitsch, R.M. Formation of neurofibrillary tangles in P3011 tau transgenic mice induced by Abeta 42 fibrils. Science 2001, 293: 1491-1495.
274. Oddo, S., Caccamo, A., Kitazawa, M., Tseng, B.P., LaFerla, F.M. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol. Aging 2003, 24: 1063-1070.
275. Spillantini,, M.G., Goedert, M. Tau protein pathology in neurodegenerative diseases. Trends Neurosci. 1998, 21: 428-433.
276. Trojanowski, J.Q. Lee, V.M. The role of tau in Alzheimer's disease. Med. Clin. North. Am. 2002, 86: 615-627.
277. Shrestha, B.R., Vitolo, ON., Joshi, P., Lordkipanidze, T., Shelanski, M., Dunaevsky, A. Amyloid beta peptide adversely affects spine number and motility in hippocampal neurons. Mol. Cell Neurosci. 2006, 33: 274-282.
278. Shankar, G.M., Bloodgood, B.L., Townsend, M., Walsh, D.M., Selkoe, D.J., Sabatini, B.L. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 2007, 27: 2866-2875.
279. De Felice, E.G., Velasco, P.T., Lambert, M.P., Viola, K.L., Fernandez, S.J., Ferreira, S.T., Klein, W.L. Aβ oligomers induce neuronal oxidative stress through an NMDA receptor-dependent mechanism that is blocked by the Alzheimer's drug memantine. J. Biol. Chem. 2007, 282 (15):11590-601.
280. Bush, A.I., Pettingell, W.H., Multhaup, G., Paradis, M., Vonsattel, J.P., Gusella, J.F., Beyreuther, K., Masters, C.L., Tanzi, R.E. Rapid induction of Alzheimer A beta amyloid formation by zinc. Science 1994, 265: 1464-1467.
281. Frederickson, C.J. Bush, A.I. Synaptically released zinc: Physiological functions and pathological effects. Biometals 2001, 14: 353-366.
282. Kayed, R., Sokolov, Y., Edmonds, B., McIntire, T.M., Milton, S.C., Hall, J.E., Glabe, C.G. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J. Biol. Chem. 2004, 279: 46363-46366.
283. Small, D.H., Maksel, D., Kerr, M.L., Ng, J., Hou X., Chu, C., Mebrain, H., Unabia, S., Azari, M.F., Loiacono, R., Aguilar, M.I., Chebib, M. The beta-amyloid protein of Alzheimer's disease binds to membrane lipids but does not bind to the alpha7 nicotinic acetylcholine receptor. J. Neurochem. 2007, 101: 1527-1538.
284. Urbane, B., Cruz, L., Buldyrev, S.V., Havlin, S., Irizarry, M.C., Stanley, H.E., Hyman, B.T. Dynamics of plaque formation in Alzhermer's disease. Biophys. J. 1999, 76: 1330-1334.
285. Coleman, P., Federoff, H., Kurlan R,. A focus on the synapse for neuroprotection in Alzheimer disease and other dementias. Neurology 2004, 63: 1155-1162.
286. Kennedy, M.B., Beale, H.C., Carlisle, H.J., Washburn, L.R. Integration of biochemical signalling in spines. Nat. Rev. Neurosci. 2005, 6: 423-434.
287. Arendt, T. Synaptic plasticity and cell cycle activation in neurons are alternative effector pathways: the 'Dr. Jekyll and Mr. Hyde concept' of Alzheimer's disease or the yin and yang of neuroplasticity. Prog. Neurobiol. 2003, 71: 83-248.
288. Venkitaramani, D.V., Chin, J., Netzer, W.J., Gouras, G.K., Lesne, S., Malinow R., Lombroso, P.J. Beta-amyloid modulation of synaptic transmission and plasticity. J. Neurosci. 2007, 27: 11832-11837.
289. Rowan, M.J., Klyubin, I., Wang, Q.W., Anwyl, R. Mechanisms of the inhibitory effects of amyloid beta-protein on synaptic plasticity. Exp. Gerontol. 2004, 39: 1661-1667.
290. Butterfield, D.A., Reed, T., Newman, S.F., Sultana, R. Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic. Biol. Med. 2007, 43: 658-677.
291. Lu, T., Pan, Y., Kao, S.Y., Li, C., Kohane, I., Chan, J., Yankner, B.A. Gene regulation and DNA damage in the ageing human brain. Nature 2004, 429: 883-891.
292. Mattson, M.P. Calcium and neurodegeneration. Aging Cell 2007, 6: 337-350.
293. Stutzmann, G.E. The pathogenesis of Alzheimers disease is it a lifelong "calciumopathy"? Neuroscientist 2007, 13: 546-559.
294. Chen, C. beta-Amyloid increases dendritic Ca2+ influx by inhibiting the A-type K+ current in hippocampal CA1 pyramidal neurons. Biochem. Biophys. Res. Commun. 2005, 338: 1913-1919.
295. Sheng, M., Hoogenraad, C.C. The postsynaptic architecture of excitatory synapses: a more quantitative view. Annu. Rev. Biochem. 2007, 76: 823-847.
296. Mishizen-Eberz, A.J., Rissman, R.A., Carter, T.L., Ikonomovic, M.D., Wolfe, B.B., Armstrong, D.M. Biochemical and molecular studies of NMDA receptor subunits NR1/2A/2B in hippocampal subregions throughout progression of Alzheimer's disease pathology. Neurobiol. Dis. 2004, 15: 80-92.
297. Sze, C., Bi, H., Kleinschmidt-DeMasters, B.K., Filley, C.M., Martin, L.J. N-Methyl-D-aspartate receptor subunit proteins and their phosphorylation status are altered selectively in Alzheimer's disease. J. Neurol. Sci. 2001, 182: 151-159.
298. Parsons, C.G., Stoffler, A., Danysz, W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse. Neuropharmacology 2007, 53: 699-723.
299. Halpain, S., Hipolito, A., Saffer, L. Regulation of F-actin stability in dendritic spines by glutamate receptors and calcineurin. J. Neurosci. 1998, 18: 9835-9844.
300. Braithwaite, S.P., Paul, S., Naim, A.C., Lombroso, P.J. Synaptic plasticity: one STEP at a time. Trends Neurosci. 2006, 29: 452-458.
301. Wang, H.Y., Lee, D.H., D'Andrea, M.R., Peterson, P.A., Shank, R.P., Reitz, A.B. beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J. Biol. Chem. 2000, 275: 5626-5632.
302. Pettit, D.L., Shao, Z., Yakel, J.L. beta-Amyloid(1-42) peptide directly modulates nicotinic receptors in the rat hippocampal slice. J. Neurosci. 2001, 21: RC120.
303. Liu, Q., Kawai, H., Berg, D.K. beta -Amyloid peptide blocks the response of alpha 7-containing nicotinic receptors on hippocampal neurons. Proc. Natl. Acad. Sci. USA 2001, 98: 4734-4739.
304. Dineley, K.T., Westerman, M., But, D., Bell, K., Ashe, K.H., Sweatt J.D. Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. J. Neurosci. 2001, 21: 4125-4133.
305. Zamani, M.R., Allen, Y.S., Owen, G.P., Gray, J.A. Nicotine modulates the neurotoxic effect of beta-amyloid protein(25-35) in hippocampal cultures. Neuroreport 1997, 8: 513-517.
306. Parameshwaran, K., Sims, C., Kanju, P., Vaithianathan, T., Shonesy, B.C., Dhanasekaran, M., Bahr, B.A., Suppiramaniam, V. Amyloid beta-peptide A beta(1-42) but not A beta(1-40) attenuates synaptic AMPA receptor function. Synapse 2007, 61: 367-374.
307. Ikonomovic, M.D., Mizukami, K., Davies, P., Hamilton, R., Sheffield, R., Armstrong, D.M. The loss of GluR2(3) immunoreactivity precedes neumfibrillary tangle formation in the entorhinal cortex and hippocampus of Alzheimer brains. J. Neuropathol. Exp. Neurol. 1997, 56: 1018-1027.
308. Armstrong, D.M., Ikonomovic, M.D. AMPA-selective glutamate receptor subtype immunoreactivity in the hippocampal dentate gyrus of patients with Alzheimer disease. Evidence for hippocampal plasticity. Mol. Chem. Neuropathol. 1996, 28: 59-64.
309. Snyder, E.M., Philpot, B.D., Huber, K.M., Dong, X., Fallon, J.R., Bear, M.F. Internalization of ionotropic glutarnate receptors in response to mGluR activation. Nat. Neurosci. 2001, 4: 1079-1085.
310. Vanderklish, P.W., Edelman, G.M. Dendritic spines elongate after stimulation of group 1 metabotropic glutamate receptors in cultured hippocampal neurons. Proc. Natl. Acad. Sci. USA 2002, 99: 1639-1644.
311. Chin, J.H., Ma, L., MacTavish, D., Jhamandas, J.H. Amyloid beta protein modulates glutamate-mediated neurotransmission in the rat basal forebrain: involvement of presynaptic neuronal nicotinic acetylcholine and metabotropic glutamate receptors. J. Neurosci. 2007, 27: 9262-9269.
312. Calabrese, B., Wilson, M.S., Halpain, S. Development and regulation of dendritic spine synapses. Physiology 2006, 21: 38-47.
313. Dalva, M.B., Takasu, M.A., Lin, M.Z., Shamah, S.M., Hu, L., Gale, N.W., Greenberg, M.E. EphB Receptors Interact with NMDA Receptors and Regulate Excitatory Synapse Formation. Cell 2000, 103: 945-956.
314. Henkemeyer, M., Itkis, O.S., Ngo, M., Hickmott, P.W., Ethell, I.M. Multiple EphB receptor tyrosine kinases shape dendritic spines in the hippocampus. J. Cell. Biol. 2003, 163: 1313-1326.
315. Penzes, P., Beeser, A., Chernoff, J., Schiller, M.R., Eipper, B.A., Mains, R.E., Huganir, R.L. Rapid induction of dendritic spine morphogenesis by trans-synaptic ephrinB-EphB receptor activation of the Rho-GEF kahrin. Neuron 2003, 37: 263-274.
316. Bagrodia, S., Cerione, R.A. Pak to the future. Trends Cell Biol. 1999, 9: 350-355.
317. Zhao, L., Ma, Q.L., Calon, F., Harris-White, M.E., Yang, F., Lim, G.P., Morihara, T., Ubeda, O.J., Ambegaokar, S., Hansen, J.E., Weisbart, R.H., Teter, B., Frautschy, S.A., Cole, G.M. Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. Nat. Neurosci. 2006, 9: 234-242.
318. Chetkovich, D.M., Nicoll, R.A. Organization and regulation of the postsynaptic density. In Dendrites, Stuart G, Spruston N, Hausser M, eds. (New York: Oxford University Press), 2007, 131-153.
319. Ehrlich, I., Malinow, R. Postsynaptic density 95 controls AMPA receptor incorporation during long-term potentiation and experience-driven synaptic plasticity. J. Neurosci. 2004, 24: 916-927.
320. Lin, H., Huganir, R., Liao, D. Temporal dynamics of NMDA receptor-induced changes in spine morphology and AMPA receptor recruitment to spines. Biochem. Biophys. Res. Commun. 2004, 316: 501-511.
321. Lippman, J., Dunaevsky, A. Dendritic spine morphogenesis and plasticity. J. Neurobiol. 2005, 64: 47-57.
322. Schubert, V., Dotti, C.G. Transmitting on actin: synaptic control of dendritic architecture. J. Cell Sci. 2007, 120: 205-212.
323. Ridley, A.J. Rho GTPases and actin dynamics in membrane protrusions and vesicle trafficking. Trends Cell Biol. 2006, 16: 522-529.
324. Krupp, J.J., Vissel, B., Thomas, C.G., Heinemann, S.F., West-brook, G.L. Interactions of calmodulin and alpha-actinin with the NR1 subunit modulate Ca2+-dependent inactivation of NMDA receptors. J. Neurosci. 1999, 19: 1165-1178.
325. Sekino, Y., Kojima, N., Shirao, T. Role of actin cytoskeleton in dendritic spine morphogenesis. Neurochem. Int. 2007, 51: 92-104.
326. Nakayama, A.Y. Luo, L.Q. Intracellular signaling pathways that regulate dendritic spine morphogenesis. Hippocampus 2000, 10: 582-586.
327. O'Kane, E.M., Stone, T.W., Morris, B.J. Activation of Rho GTPases by synaptic transmission in the hippocampus. J. Neurochem. 2003, 87: 1309-1312.
328. Luo, L. Rho GTPases in neuronal morphogenesis. Nat. Rev. Neurosci. 2000, 1: 173-180.
329. Tashiro, A., Minden, A., Yuste, R. Regulation of dendritic spine morphology by the rho family of small GTPases: antagonistic roles of Rac and Rho. Cereb. Cortex 2000, 10: 927-938.
330. Tashiro, A., Yuste, R. Regulation of dendritic spine motility and stability by Rac1 and Rho kinase: evidence for two forms of spine motility. Mol. Cell Neurosci. 2004, 26: 429-440.
331. Mendoza-Naranjo, A., Gonzalez-Billault, C., Maccioni R.B. Abeta(1-42) stimulates actin polymerization in hippocampal neurons through Rac1 and Cdc42 Rho GTPases. J. Cell Sci. 2007, 120: 279-288.
332. Zhu, X., Raina, A.K., Boux, H., Simmons, Z.L., Takeda, A., Smith, M.A. Activation of oncogenic pathways in degenerating neurons in Alzheimer disease. Int. J. Dev. Neurosci. 2000, 18: 433-437.
333. Arber, S., Barbayannis, F.A., Hauser, H., Schneider, C., Stanyon, C.A., Bernard, O., Caroni, P. Regulation of actin dynamics through phosphorylation of cofilin by LIM-kinase. Nature 1998, 393: 805-809.
334. Yang, N., Higuchi, O., Ohashi, K., Nagata, K., Wada, A., Kangawa, K., Nishida, E., Mizuno, K. Cofilin phosphorylation by LIM-kinase 1 and its role in Rac-mediated actin reorganization. Nature 1998, 393: 809-812.
335. Lee, M., You, H.J., Cho, S.H., Woo, C.H., Yoo, M.H., Joe, E.H., Kim, J.H. Implication of the small GTPase Rac1 in the generation of reactive oxygen species in response to beta-amyloid in C6 astroglioma cells. Biochem. J. 2002, 366: 937-943.
336. Guzowski, J.F., Lyford, G.L., Stevenson, G.D., Houston, F.P., McGaugh, J.L., Worley, P.F., Barnes, C.A. Inhibition of activity-dependent arc protein expression in the rat hippocampus impairs the maintenance of long-term potentiation and the consolidation of long-term memory. J. Neurosci. 2000, 20: 3993-4001.
337. Tzingounis, A.V., Nicoll, R.A. Arc/Arg3.1: linking gene expression to synaptic plasticity and memory. Neuron 2006, 52: 403-407.
338. Chowdhury, S., Shepherd, J.D., Okuno, H., Lyford, G., Petralia, R.S., Plath N... Kuhl, D., Huganir, R.L., Worley, P.F. Arc/Arg3.1 interacts with the endocytic machinery to regulate AMPA receptor trafficking. Neuron 2006, 52: 445-459.
339. Rial Verde, E.M., Lee-Osbourne, J., Worley, P.F., Malinow, R., Cline, H.T. Increased expression of the immediate-early gene arc/arg3.1 reduces AMPA receptor-mediated synaptic transmission. Neuron 2006, 52: 461-474.
340. Shepherd, J.D., Rumbaugh, G., Wu, J., Chowdhury, S., Plath, N., Kuhl, D., Huganir, R.L., Worley, P.F. Arc/Arg3.1 mediates homeostatic synaptic scaling of AMPA receptors. Neuron 2006, 52: 475-484.
341. Rao, V.R., Pintchovski, S.A., Chin, J., Peebles, C.L., Mitra, S., Finkbeiner, S. AMPA receptors regulate transcription of the plasticity-related immediate-early gene Arc. Nat. Neurosci. 2006, 9: 887-895.
342. Feng, J., Yan, Z., Ferreira, A., Tomizawa, K., Liauw, J.A., Zhuo, M., Allen, P.B., Ouimet, C.C., Greengard, P. Spinophilin regulates the formation and function of dendritic spines. Proc. Natl. Acad. Sci. USA 2000, 97: 9287-9292.
343. Chin, J., Palop, J.J., Yu, G.Q., Kojima, N., Masliah, E., Mucke, L. Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. J. Neurosci. 2004, 24: 4692-4697.
344. Tong, L., Thornton, P.L., Balazs, R., Cotman, C.W. Beta -amyloid-(1-42) impairs activity-dependent cAMP-response element-binding protein signaling in neurons at concentrations in which cell survival Is not compromised. J. Biol. Chem. 2001, 276: 17301-17306.
345. Vitolo, O.V., Sant'Angelo, A., Costanzo, V., Battaglia, F., Arancio, O., Shelanski, M. Amyloid beta -peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc. Natl. Acad. Sci. USA 2002, 99: 13217-13221.
346. Ferreira, A., Lu, Q., Orecchio, L., Kosik, K.S. Selective phosphorylation of adult tau isoforms in mature hippocampal neurons exposed to fibrillar A beta. Mol. Cell Neurosci. 1997, 9: 220-234.
347. Bell, K.A., O'Riordan, K.J., Sweatt, J.D., Dineley, K.T. MAPK recruitment by beta-amyloid in organotypic hippocampal slice cultures depends on physical state and exposure time. J. Neurochem. 2004, 91: 349-361.
348. Kim, H.J., Kim, J.H., Chae, S.C., Park, Y.C., Kwon, K.S., Hong, S.T. Soluble oligomeric A beta disrupts the protein kinase C signaling pathway. Neuroreport 2004, 15: 503-507.
349. Chin, J., Palop, J.J., Puolivali, J., Massaro, C., Bien-Ly, N., Gerstein, H., Scearce-Levie, K., Masliah, E., Mucke, L. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J. Neurosci. 2005, 25: 9694-9703.
350. Townsend, M., Mehta, T., Selkoe, D.J. Soluble abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J. Biol. Chem. 2007, 282: 33305-33312.
351. Xie, L., Helmerhorst, E., Taddei, K., Plewright, B., Van Bronswijk, W., Martins, R. Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor. J. Neurosci. 2002, 22: RC221.
352. Cole, G.M., Frautschy, S.A. The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer's Disease. Exp. Gerontol. 2007, 42: 10-21.
353. Takadera, T., Sakura, N., Mohri, T., Hashimoto, T. Toxic effect of a beta-amyloid peptide (beta 22-35) on the hippocampal neuron and its prevention. Neurosci. Lett. 1993, 161: 41-44.
354. Beattie, E.C., Carroll, R.C., Yu, X., Morishita, W., Yasuda, H., von Zastrow, M., Malenka, R.C. Regulation of AMPA receptor endocytosis by a signaling mechanism shared with LTD. Nat. Neurosci. 2000, 3: 1291-300.
355. Yao, P.J. Synaptic frailty and clathrin-mediated synaptic vesicle trafficking in Alzheimer's disease. Trends Neurosci. 2004, 27: 24-29.
356. Kelly, B.L., Ferreira, A. Beta-amyloid disrupted synaptic vesicle endocytosis in cultured hippocampal neurons. Neuroscience 2007, 147: 60-70.
357. Gong, B., Cao, Z.X., Zheng, P., Vitolo, O.V., Liu, S.M., Staniszewski, A., Moolman, D., Zhang, H., Shelanski, M., Arancio, O. Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell 2006, 126: 775-788.
358. Tseng, B.P., Green, K.N., Chan, J.L., Blurton-Jones, M., LaFerla, F.M. Abeta inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol. Aging. 2007 May 31 [Epub ahead of print].